MX2019003888A - Compuestos de briostatina y metodos para prepararlos. - Google Patents

Compuestos de briostatina y metodos para prepararlos.

Info

Publication number
MX2019003888A
MX2019003888A MX2019003888A MX2019003888A MX2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A
Authority
MX
Mexico
Prior art keywords
bryostatin
methods
preparing
same
subject methods
Prior art date
Application number
MX2019003888A
Other languages
English (en)
Inventor
Wender Paul
Quiroz Ryan
Ho Stephen
Ryckbosch Steven
C Stevens Matthew
S Jeffreys Matthew
HARDMAN Clayton
Sloane Jack
Shimizu Akira
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2019003888A publication Critical patent/MX2019003888A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan métodos para preparar una variedad de compuestos de briostatina. Los métodos de la presente proporcionan la preparación de briostatina 1 en cantidades de múltiples gramos en una cantidad baja y sin precedentes de etapas sintéticas convergentes a partir de materiales disponibles en el mercado. Los métodos de la presente son escalables con bajos costos de materiales estimados y pueden proporcionar una cantidad suficiente de material para satisfacer los requisitos clínicos. También se proporciona una variedad de compuestos análogos de briostatina, y formas de profármaco de estos, a los que puede accederse de manera sintética a través de los métodos de la presente y composiciones farmacéuticas que los incluyen.
MX2019003888A 2016-10-05 2017-09-28 Compuestos de briostatina y metodos para prepararlos. MX2019003888A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404687P 2016-10-05 2016-10-05
PCT/US2017/054158 WO2018067382A1 (en) 2016-10-05 2017-09-28 Bryostatin compounds and methods of preparing the same

Publications (1)

Publication Number Publication Date
MX2019003888A true MX2019003888A (es) 2019-11-28

Family

ID=61831583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003888A MX2019003888A (es) 2016-10-05 2017-09-28 Compuestos de briostatina y metodos para prepararlos.

Country Status (11)

Country Link
US (3) US10947221B2 (es)
EP (1) EP3523296A4 (es)
JP (2) JP7148147B2 (es)
CN (1) CN109923110A (es)
AU (1) AU2017339786B2 (es)
CA (1) CA3038532A1 (es)
IL (2) IL265663B (es)
MX (1) MX2019003888A (es)
TW (1) TWI754676B (es)
WO (1) WO2018067382A1 (es)
ZA (1) ZA201902089B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947221B2 (en) 2016-10-05 2021-03-16 The Board Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
SG11202112873RA (en) * 2019-05-21 2021-12-30 Univ Leland Stanford Junior Bryostatin compounds for enhancement of immunotherapy
CN112209812B (zh) * 2019-07-11 2021-12-07 中国科学院大连化学物理研究所 一种1,1-二芳基-2-烷基乙烯衍生物及其合成方法
WO2022036335A1 (en) * 2020-08-09 2022-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Organ transplant perfusion solution modifications using bryostatin-1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358711A (en) 1987-11-23 1994-10-25 Johns Hopkins University Stimulation of stem cell growth by the bryostatins
US5440055A (en) 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
CN1062866C (zh) * 1997-10-31 2001-03-07 中国人民解放军第二军医大学药学院 一种新的抗癌活性化合物草苔虫内酯
JP2003515601A (ja) * 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2003093275A1 (en) * 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill A bryostatin composition
US8497385B2 (en) * 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009052507A1 (en) 2007-10-19 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009129361A2 (en) 2008-04-16 2009-10-22 University Of Utah Research Foundation Macrocyclic compounds and methods of making and using thereof
US8816122B2 (en) * 2009-07-20 2014-08-26 The Board Of Trustees Of The Leland Stanford Junior University Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use
ES2905359T3 (es) * 2012-04-26 2022-04-08 Univ Yale Moléculas de suministro de fármacos citotóxicos dirigidas al VIH (CDM-H), actividad citotóxica contra el virus de la inmunodeficiencia humana y métodos de uso
HUE041497T2 (hu) 2014-02-14 2019-05-28 Cellectis Immunsejteken és patológiás sejteken egyaránt jelen lévõ antigént célzó génmódosított sejtek immunterápia célra
US20170239212A1 (en) 2014-08-11 2017-08-24 University Of Utah Research Foundation Bryostatin analogs and use thereof as antiviral agents
US10947221B2 (en) 2016-10-05 2021-03-16 The Board Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
JP7314115B2 (ja) 2017-03-31 2023-07-25 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
JP7459043B2 (ja) 2018-07-12 2024-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
SG11202112873RA (en) * 2019-05-21 2021-12-30 Univ Leland Stanford Junior Bryostatin compounds for enhancement of immunotherapy

Also Published As

Publication number Publication date
EP3523296A1 (en) 2019-08-14
US11746105B2 (en) 2023-09-05
WO2018067382A1 (en) 2018-04-12
IL265663B (en) 2021-10-31
AU2017339786A1 (en) 2019-05-02
US20240116908A1 (en) 2024-04-11
JP2019531295A (ja) 2019-10-31
JP7148147B2 (ja) 2022-10-05
US10947221B2 (en) 2021-03-16
CA3038532A1 (en) 2018-04-12
AU2017339786B2 (en) 2021-09-02
CN109923110A (zh) 2019-06-21
IL287119B2 (en) 2023-07-01
TWI754676B (zh) 2022-02-11
EP3523296A4 (en) 2020-04-01
ZA201902089B (en) 2020-10-28
JP2022107010A (ja) 2022-07-20
IL265663A (en) 2019-05-30
US20190292172A1 (en) 2019-09-26
IL287119A (en) 2021-12-01
US20210292309A1 (en) 2021-09-23
IL287119B1 (en) 2023-03-01
TW201815795A (zh) 2018-05-01

Similar Documents

Publication Publication Date Title
MX2019003888A (es) Compuestos de briostatina y metodos para prepararlos.
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
MY193728A (en) Muscarinic receptor agonists
BR112013026363A2 (pt) nanossuspensões de fármaco criodessecadas
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
CL2008002809A1 (es) Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
PH12016500988A1 (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
MX2015017011A (es) Compuestos nuevos para el tratamiento del cancer.
MX2014012164A (es) Composiciones a base de probioticos y un complejo de polen de abejas/arcilla, su preparacion y sus usos en nutricion y en terapeutica.
MX2018006226A (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
UA120083C2 (uk) АНТИМЕТАСТАТИЧНІ 2H-СЕЛЕНОФЕНО[3,2-h]ХРОМЕНИ, ЇХ СИНТЕЗ ТА СПОСОБИ ЗАСТОСУВАННЯ ЦИХ АГЕНТІВ
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
MX2019011286A (es) Carboxamidas heteroaromaticas sustituidas de piperidinilo y piperazinilo como moduladores de gpr6.
IN2013MU01177A (es)
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
PL408608A1 (pl) Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
IN2014MN01492A (es)
PH12019550098A1 (en) Nutritional composition in powder form provided in single serving capsules
MX346497B (es) Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos.
EP2992885A3 (en) Method for inhibiting a liver disease
EP2918291A3 (en) Pharmaceutical composition of stabilized paracetamol, plastic bags and use of the pharmaceutical composition